Moderna stock's recent surge might herald a shift in AI-focused dollars away from memory and data-center plays … and toward applications of generative AI tech. On Wednesday, Cambridge, Mass.-based Moderna (MRNA) soared 177% to hit a three-year high after announcing positive results in testing a vaccine for certain types of cancer. The tests showed a lengthening in relapses among patients…